The global biodefense market size is expected to reach USD 15.62 Billion in 2021 and register a revenue CAGR of 8.7% during the forecast period. Rising research & development initiatives in the field of biodefense, increasing investments and initiatives by governments of various countries for biodefense activities, growing incidence of infectious diseases and viral outbreaks such as SARS-CoV 2, growing awareness regarding biological threats, and rapid technological developments in the field of biodefense techniques are key factors expected to drive market revenue growth during the forecast period.
Biodefense refers to interventions, such as vaccinations, drugs, and surveillance of pathogens, among others, along with extensive R&D activities and community health preparations, to counter bioterrorism. Bioterrorism has the potential to cause severe morbidity and mortality as aerosolized bioweapons can infect and harm a large number of people in a short period of time. Non-aerosolized bio attacks, such as the anthrax bioterrorism attack, possess the potential to cause considerable morbidity and fatality, necessitating large-scale healthcare, public health emergency preparedness, and biological disaster response. As a result, biodefense consists of medical measures that are taken to restore the bio-security of a country by providing protection against potential infectious agents or biotoxins having the potential to infect and cause harm to humans, animals, or to initiate biological warfare.
Throughout history, infectious diseases with pandemic potential have occurred. Some examples include SARS Coronavirus (SARS CoV), H1N1 influenza A, Middle East Respiratory Syndrome Coronavirus (MERS CoV), West Nile virus, and other viruses. Although the future impact of emerging infections is unknown, infectious diseases are predicted to continue to originate or resurface, resulting in epidemics of various proportions. Thus, rapid actions taken for disease control constitute the first line of action in biodefense and it is of critical importance to control the initial wave of a disease to prevent community spread. Biosurveillance is an emerging field that involves expanding standard public health monitoring to identify and anticipate bio-terrorist threats and disease outbreaks in humans, plants, and animals. Biosurveillance appears to have benefited the most from developing biotechnologies, particularly from the integration and analysis of varied demographic, biological, clinical, and other essential data. Many public health systems put a strong emphasis on improving the performance of bio-surveillance programs and utilizing new technology to improve data collection and analysis. As a result, organizations such as the Centers for Disease Control and Prevention (CDC) in the U.S. have invested in projects such as BioSense, which is designed to boost emergency preparedness in the country through the establishment of a strong network for real-time detection of disease, monitoring, and health situational awareness.
Request a Sample@ https://qyresearchmedical.com/sample/119036
In the last few decades, advances in genetic engineering and biotechnology have made it much easier to manipulate deadly and naturally existing viruses, which can now be reengineered to cause much more harm. Nanotechnology and biotechnology are emerging as new frontiers in biodefense and technological advancements in these fields are leading to the development of advanced biosensor technology, which can differentiate between pathogens and benign microorganisms. The introduction of novel biotechnologies holds a strong potential for biodefense, particularly for critical objectives such as biosurveillance, microbial forensics, biotechnology horizon scanning, risk assessment, and Medical Countermeasure (MCM) development. Scientists have recently begun to apply synthetic biology and genomics for the development of novel MCM-based products and platforms.
Genomic technologies are accelerating growth of genomic data, which ranges from genetic sequences and entire genomes to data that connects genes to specific features and other sorts of information for humans, animals, plants, and microorganisms. This information is already becoming increasingly digitized and advances in computing power are altering how genomic data is analyzed. The private sector has played a key role in the development of data mining algorithms and techniques. For instance, DeepVariant, Google’s genomic Artificial Intelligence (AI) platform, has been at the forefront of creating an automated, deep learning technique for detecting genetic variants in an individual genome from billions of short sequences. A biodefense enterprise that uses Deoxyribonucleic acid (DNA) information, and AI approaches can assist organizations and individuals in fully utilizing a vast collection of heterogeneous, unstructured quantitative and qualitative information. This method could be beneficial for identifying potential vulnerabilities in strategies, tactics, and measures, but more critically, it could be used to avoid proliferators’ deception. Governments and private companies will be able to sort, categorize, trade, and use biological data far more precisely than ever before, creating unprecedented possibilities for social and biological control. This is a major factor expected to drive market revenue growth.
The market is expected to offer major growth opportunities for key pharmaceutical companies in the market, with governments across the globe engaging in drafting policies and strategies pertaining to biodefense and biosecurity.
Governments of many countries are at the forefront to deal with unprecedented outbreaks of infectious diseases in various ways, such as by establishing research laboratories, and clinical testing centers, collecting information for surveillance, and providing funds on a regular interval to prepare for unforeseen circumstances in the future. This, in turn, is helping various private pharmaceutical companies to establish themselves by getting subsidies and other licensing support for manufacturing vaccines and other drugs. Moreover, various awareness programs are allowing companies to expand their customer base, which is also expected to drive market revenue growth.
Driver: Rapid government funding & protective measures against bioterrorism
The market is projected to grow owing to increased funding for R&D efforts by the biopharmaceutical and pharmaceutical industries. Biodefense market is expected to grow owing to new product launches, increased government investments, and measures that will improve the biotech sector in emerging economies. Rising defense spending by governments around the world is strengthening both external as well as internal security, which is driving market growth.
Moreover, governments across the globe are investing a substantial amount of funds in advanced R&D activities with the aim to achieve medical countermeasure preparedness against biological threats. For instance, the National Institutes of Health (NIH), the Department of Homeland Security (DHS), the United States Agency for International Development (USAID), and the Department of Defense (DoD) launched programs to improve understanding of pathogenic organisms of national security concern, disease dynamics, and host-pathogen interactions by modeling the growth and spread of infectious diseases. In addition, these agencies embraced the advances in computational and data science, modern biotechnologies, and the integration of chemical, biological, and other disciplines to develop novel approaches for identifying and responding to biological threats.
Restraint: High costs of advanced biodefense technologies and equipment
Inadequate funding capacity of developing and underdeveloped countries to build strong biodefense mechanisms could hamper market revenue growth to some extent. The development of biodefense mechanisms requires access to advanced technologies, well-equipped laboratories, and expert professionals in the field. Additionally, the presence of established infrastructure, including proper transportation and distribution facilities to remote areas, where accessibility is tough due to difficult terrains or harsh weather conditions, is also necessary. A large section of the population in various underdeveloped countries can become victims of biowarfare due to a lack of adequate facilities and funds for research & development of vaccines and novel drugs.
During the COVID-19 pandemic, various pharmaceutical companies were working on developing vaccines to protect people from the coronavirus. These vaccines were quite effective and efficacious in clinical trials at different phases and were subsequently approved by the Food and Drug Administration (FDA) and other central drug authorities of various countries. Post lockdown, economic activities resumed and several other vaccines were manufactured at a steady pace as per the requirement. Bulk orders posted previously from developed and developing countries for COVID-19 vaccine were effectively rolled out and given to individuals in a phased manner. Governments of various countries have started conducting awareness programs for mass vaccination to curb the spread of the disease. Demand for these vaccines is very high but they are unaffordable to many underdeveloped countries, which is compelling World Health Organization (WHO) to take initiatives to purchase vaccines for underdeveloped countries and supply them for free, in order to ensure that vaccines reach every citizen of the world. Such initiatives are driving market revenue growth, and moreover, inclusion of booster shots is expected to help the market to grow at a faster rate during the forecast period.
Product Type Insights:
On the basis of product type, the global biodefense market is segmented into anthrax vaccine, smallpox vaccine, botulism vaccine, radiation vaccine, and others. Anthrax vaccine segment accounted for largest revenue share in 2021, which can be attributed to an increase in government spending across the globe to develop and store sufficient anthrax vaccines. Anthrax is a life-threatening disease caused by the ‘Bacillus anthracis’ bacterium, and hence its vaccine has been a life-saver. Anthrax vaccine is given to people in the age group of 18-65 years who are at a high risk of exposure to anthrax, and this is expected to drive revenue growth of the segment.
Radiation vaccine segment is expected to register a faster revenue CAGR during the forecast period, owing to efficient radioprotection and immunotherapy of acute radiation syndromes offered by radiation vaccines, after neutron irradiation, gamma-irradiation, or heavy-ion irradiation. Furthermore, radiation vaccines can provide reliable protection to non-neoplastic areas of cancer patients who undergo heavy ion therapy, and significantly extend efficiency of the therapeutic course. This, in turn, is expected to increase their adoption and thus, drive revenue growth of the segment.
On the basis of application, the global biodefense market is segmented into military and civilian. Civilian segment is expected to register a rapid revenue CAGR during the forecast period, owing to increasing biological threats to civilians from terrorist organizations. Most terrorist organizations cause disruptions in society and as major part of the society is occupied by civilians, so major damage or biological threat is faced by the civilians section, that’s why, governments are coming up with civilian biodefense strategies and research activities in order to prepare the civilian population from such biological attacks. Many research institutions are conducting civilian biodefense research as a result of the emergence of new potentially lethal viruses, such as avian influenza, which can occur naturally or be purposefully introduced by terrorists. For example, NIAID’s civilian biodefense research is incorporated within its larger portfolio of emerging and reemerging infectious illnesses. NIAID was given lead responsibility for civilian biodefense research within the U.S. Department of Health and Human Services (HHS) and the National Institutes of Health (NIH), with an emphasis on research and initial advancements in medical countermeasures against terrorist activities from infectious diseases as well as exposure to radiation. This is a major factor that is expected to drive revenue growth of the segment during the forecast period.
On the basis of end-use, the global biodefense market is segmented into hospitals, clinics, and others. Hospitals segment accounted for largest revenue share in 2021 and is expected to register a faster revenue CAGR during the forecast period. Growth of this segment can be attributed to presence of extensive R&D facilities and availability of data of patients prone to infectious diseases in the past. Hospitals can provide an all-around approach to dealing with disease outbreaks to save as many lives as possible owing to the presence of well-qualified doctors, public health experts, and laboratories. Hospitals and medical colleges are keen on developing new technologies to handle any future unforeseen circumstances with immediate effect. Many military hospitals and research centers funded by governments for biodefense encompass basic research and genomic research, along with development of new vaccines, therapies, and diagnostics to protect civilians against biological threats. Thus, expansion of research infrastructure is expected to drive segment revenue growth.
Based on regional analysis, biodefense market in North America accounted for largest revenue share in 2021, which can be attributed to high federal funding by the U.S. for the development of biodefense strategies, technological advancements, and growing awareness among the population. Presence of major companies in the region is also expected to play an important role in market expansion. Furthermore, strategies for establishment of a biodefense mechanism and emergency response in case of biological outbreaks are expected to drive market revenue growth. The FY23 Budget released by the U.S. government included a historic USD 88.2 billion mandatory funding which will be available for over five years, across the Department of Health and Human Services (HHS), the Centers for Disease Control and Prevention (CDC), the National Institutes of Health (NIH), the Department of State, and the United States Agency for International Development (USAID) to prepare for future biological threats in support of objectives within U.S. national and global biodefense and pandemic preparedness strategies and plans. This investment will fund significant advances and improvements to identify, prevent, and provide a protective response to emerging biological disasters.
Biodefense market in Asia Pacific is expected to register a faster revenue CAGR during the forecast period, owing to increasing investments in R&D and growing incidents of biothreats in the region. Governments of countries in the region are subsidizing companies with adequate funding and easy clearance of licenses for establishing factories and manufacturing plants for vaccine and drug development, which is also supporting market growth in Asia Pacific.
Biodefense market in Europe accounted for second-largest revenue share in 2021 owing to regulations of biosecurity imposed by different countries in the region. For instance, Germany has biosecurity legislation, Technical Rules for Biological Agents (TRBA) 100, which addresses requirements such as operation practices, physical containment, and failure reporting systems of institutions or facilities in which dangerous toxins and pathogens are stored or processed. Such stringent measures are driving market revenue growth in the region.
Competitive landscape of global biodefense market is moderately fragmented with many key companies operating at global and regional levels. Major companies are engaged in research and development initiatives and testing and entering into alliances to develop and introduce more novel and innovative products. Some major companies operating in the global market report include Altimmune Inc., Emergent BioSolutions Inc., SIGA Technologies Inc., Ichor Medical Systems Inc., Elusys Therapeutics Inc., Alnylam Pharmaceuticals Inc., Dynavax Technologies Corporation, Ology Bioservices Inc., Dynport Vaccine Company LLC, and Cleveland Biolabs Inc.
- On 28 December 2021, Dynavax Technologies Corporation announced that Biological E’s CORBEVAX COVID-19 vaccine, which contains Dynavax’s CpG 1018 adjuvant, got approved for emergency use by the Drugs Controller General of India. Dynavax is to supply CpG 1018 adjuvant to Biological E to meet their needs for the existing contract with the Government of India for 300 million doses, as well as additional adjuvant required to fulfil future demand in 2022 and beyond.
- On 4 October 2021, Dynavax Technologies Corporation and the U.S. Department of Defense (DOD) announced an agreement for approximately USD 22 Million over two and a half years, to develop a recombinant plague vaccine using Dynavax’s CpG 1018 adjuvant. Under the agreement, Dynavax will conduct a Phase 2 clinical trial combining its CpG 1018 adjuvant with the DOD’s rF1V vaccine.
Segments Covered in the Report
This report offers historical data and forecasts revenue growth at a global, regional, and country-level, and provides analysis of market trends in each of sub-segments from 2022 to 2030. For the purpose of this report, Reports and Data has segmented the global biodefense market based on product type, application, end-use, and region:
Biodefense Market Report Scope
Segments covered By Product Type Outlook, Application Outlook, End-use Outlook, Regional Outlook
By Product Type Outlook
By Application Outlook
By End-use Outlook
Middle East & Africa
Buy quantitative research Report at discounted price – USD 1500 https://qyresearchmedical.com/report/checkout/119036/1500
You can place an order or ask any questions, please feel free to contact email@example.com | +1 9197 992 333
QYResearch Medical has more than 4000 global well-known customers, covering more than 30 industries including pharmaceuticals, medical technology & devices, healthcare services etc. Company services cover one-stop solution as Data-Analysis-Suggestion-Consulting Implementation. Research regions cover North America, Europe, Latin America, Middle East and Africa, Asia- Pacific.
For Latest Update Follow Us: